Blocking this myeloid checkpoint CD47-SIRP⍺ axis using anti-CD47 antibody therapy was shown to limit tumor growth in both adult and pediatric gliomas [40,41] and also promoted M1 activation of TAMs [42]. This evidence concerns the gene CD47 and neoplasm.